[EN] ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY<br/>[FR] ANTAGONISTES DOUBLES DU RÉCEPTEUR A2A ET DU RÉCEPTEUR A2B DE L'ADÉNOSINE POUR L'IMMUNO-ONCOLOGIE
申请人:MERCK SHARP & DOHME
公开号:WO2022020550A1
公开(公告)日:2022-01-27
The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.